Insights
Our Insights series brings you perspectives on biosimilars from key leaders in the field.
Experts in the field of biosimilars wrap up their discussion by considering what must be done to educate pharmacists, nurses, and patients about biosimilars.
Key opinion leaders enumerate the challenges of biosimilars to providers and payers, including patient education, and addressing concerns.
Ali McBride, PharmD, MS, BCOP, FAzPA, FASHP, and Kashyap Patel, MD, consider the key factors that determine whether a specific biosimilar will be included in an individual health plan formulary.
A discussion on the role of insurance companies and pharmacy benefit managers (PBMs) in determining access to biosimilars.
.png "The Economic Impact of Biosimilars")
Experts in the field of biosimilars assess the financial value of biosimilars and consider the factors that limit cost-saving potential.
Key opinion leaders discuss patient support programs and other resources to improve patient access to biologics.
A consideration of how biologics have impacted the cancer treatment landscape.
Ali McBride, PharmD, MS, BCOP, FAzPA, FASHP, and Kashyap Patel, MD, provide insight into how they choose the appropriate biosimilar—over other biologics—for individual patient needs.
Experts in the field of biosimilars consider the possibility of biosimilar interchangeability and the general confidence of biosimilars among providers.
A discussion on the process for biosimilars to achieve FDA approval.
